DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2005-04-06

Last Posted Date: 2013-11-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 37

Registration Number: NCT00107159

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: celecoxib

First Posted Date: 2005-03-04

Last Posted Date: 2015-10-02

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT00104767

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2005-01-10

Last Posted Date: 2013-07-10

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00100997

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer

First Posted Date: 2004-12-09

Last Posted Date: 2008-01-28

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT00098917

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2004-12-08

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00098462

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Ovarian Cancer

First Posted Date: 2004-11-09

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00096239

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-11-09

Last Posted Date: 2013-06-26

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT00096057

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Phase 1

Terminated

Conditions: Lymphoma
Lymphoproliferative Disorder

Interventions: Drug: bortezomib + ganciclovir

First Posted Date: 2004-10-08

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT00093704

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

BMS-599626 in Treating Patients With Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: BMS-59926

First Posted Date: 2004-10-08

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT00093730

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer

Phase 1

Withdrawn

Conditions: Liver Cancer

First Posted Date: 2004-10-08

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00093548

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy